Novartis Drug First to Cross Oral MS Therapy Finish Line in U.S.


Published On: September 23rd, 2010

The FDA said today it approved the Swiss drug maker’s Gilenya (known generically as fingolimod) for use against the most common type of MS.

Read more from the original source: 
Novartis Drug First to Cross Oral MS Therapy Finish Line in U.S.



Loading...


Comments are closed.